|
Mr. Rohn has over 30 years of management experience in the biotechnology and pharmaceutical industry including more than 10 years in executive management positions at Idec Pharmaceuticals Inc. and, more recently, Biogen Idec where he served as Chief Operating Officer. He joined Idec in August 1993 as Senior Vice President, Commercial and Corporate Development, was appointed Senior Vice President, Commercial Operations in April 1996 and was promoted to Chief Operating Officer in May 1998. In January 2002, he became President, responsible for Sales, Marketing, Business Development, Manufacturing, Quality, Medical Affairs and CMC Regulatory Affairs. He was responsible for building Idec's initial commercial infrastructure to support the launch of Rituxan, the first monoclonal antibody approved in the United States for the treatment of cancer. Prior to joining Idec, Mr. Rohn held marketing and sales management positions at Adria Laboratories, now part of Pfizer, Abbott Laboratories, Warren-Teed Pharmaceuticals, Miles Laboratories and Mead Johnson Laboratories. Mr. Rohn serves on the Board of Directors of Pharmacyclics, Inc., Metabasis Therapeutics, Inc. and Cerus Corporation. Mr. Rohn received a B.A. in Marketing from Michigan State University. In late 2004 Mr. Rohn announced his retirement from Biogen Idec, effective January 31, 2005. | 